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Purpose
Bromelain, a pineapple extract, is a complex mixture of
proteases and protease inhibitors. Although bromelain
(Br) has been used clinically for over 40 years, the active
constituents that mediate its anti-inflammatory activity
are not thoroughly characterized and no biomarker
exists to evaluate absorbed peptides and their potential
therapeutic responses.
Methods
Stem Br (Vital Nutrients lot # 2890; Middletown, CT),
was tested for authenticity and purity. Female C57BL/6J
mice, (Jackson Laboratory; Bar Harbor, ME) received
one bolus, i.p. injection of Br (12mg/kg) in 0.5ml of phy-
siological saline and plasma collected at baseline 3, 6, 12
and 24 hours. All procedures were approved by the Ani-
mal Care Committee at University of CT Health Center.
Post SDS-PAGE in gel digestion, samples (Br raw mate-
rial, spiked plasma and plasma from i.p. teated animals)
were analyzed via LC/MS/MS (Liquid Chromatography-
Mass Spectrometry-Mass) and LC-SRM/MS (Liquid
Chormatography-Selected Reaction Monitoring/Mass
Spectrometry). Data were searched using Mascot and
Scaffold algorithms.
Results
Within the Br raw material we identified 44 proteins
of which several were Br-specific including nine pro-
teases, one glycosidase and three protease inhibitors.
In Br spiked plasma, 7 Br-specific proteins (ananain,
Br inhibitor, comosain, cysteine proteinase precursor
ANll, FB1035 precursor, FBSB precursor and jacalin-
like lectin), similar to those found in the Br raw mate-
rial, were identified. Within these 7 proteins, 21 Br-
specific peptides were further identified and charac-
terized based on their ion spectrum and fragmenta-
tion patterns including the unique peptide,
DYGAVNEVK. Using SRM DYGAVNEVK was identi-
fied in plasma of Br-treated mice. The spectral count
of DYGAVNEVK peaked at 6 hours and was unde-
tectable by 24 hours.
Conclusion
This Br peptide could serve as a biomarker to standar-
dize the therapeutic dose or Br and maximize its clinical
utility.
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